AbbVie Inc. (ABBV)
How ABBV actually reacts to news — the realized, point-in-time move the market made, measured across 720 labeled events over the last three years with zero look-ahead.
ABBV’s median reaction, across the day.
Half of all AbbVie Inc. news events land between -0.35% and +0.52% at 30 minutes.
Reaction stats as of 2026-08-18. Reaction = percent move vs. the price at the news timestamp.
Email me when ABBV moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ABBV’s baseline. Nothing else.
Get “How ABBV reacts to news” as a PDF.
A free one-page summary: ABBV’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.
Recent ABBV events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support | Press release | PR Newswire | +0.16% | +1.83% | |
| Form 8-K AbbVie Inc. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +1.25% | |
| Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices | Press release | PR Newswire | +0.04% | +0.79% | |
| Form 8-K AbbVie Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -2.08% | |
| Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence | Press release | PR Newswire | -0.96% | -1.19% | |
| UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment | Press release | Canada Newswire | -0.96% | -1.19% | |
| Form 10-Q AbbVie Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.10% | -0.56% | |
| AbbVie Reports Second-Quarter 2026 Financial Results | Press release | PR Newswire | +2.51% | +1.59% | |
| Form 8-K AbbVie Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +2.51% | +1.59% | |
| JUVÉDERM® Day Returns to U.S. on August 19 | Press release | PR Newswire | +1.31% | +0.63% | |
| AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo | Press release | PR Newswire | -0.09% | -0.34% | |
| AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata | Press release | PR Newswire | -0.09% | -0.34% | |
| Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients | Press release | PR Newswire | +0.23% | -1.04% | |
| SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development | Press release | PR Newswire | -0.43% | -0.49% | |
| AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma | Press release | PR Newswire | -0.02% | -0.67% | |
| Form 8-K AbbVie Inc. For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -0.98% | |
| AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Press release | PR Newswire | -0.23% | -1.25% | |
| AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo | Press release | PR Newswire | -1.06% | +0.75% | |
| AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata | Press release | PR Newswire | -1.06% | +0.75% | |
| AbbVie to Host Second-Quarter 2026 Earnings Conference Call | Press release | PR Newswire | +0.91% | +3.25% | |
| SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease | Press release | PR Newswire | -1.06% | +0.75% | |
| BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026 | Press release | PR Newswire | -0.46% | -0.62% | |
| Form 11-K AbbVie Inc. For: Dec 31 | SEC filing · Form 11-K | SEC EDGAR | +0.11% | +2.59% | |
| AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection | Press release | PR Newswire | -1.05% | +0.24% | |
| AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis | Press release | PR Newswire | -1.05% | +0.24% | |
| Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients | Press release | PR Newswire | -1.05% | +0.24% | |
| AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio | Press release | PR Newswire | +1.12% | +3.08% | |
| Form 8-K AbbVie Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +1.12% | +3.08% | |
| AbbVie Declares Quarterly Dividend | Press release | PR Newswire | +1.12% | +3.08% | |
| Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance | Press release | PR Newswire | -0.35% | -0.38% | |
| AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results | Press release | PR Newswire | -0.04% | +0.11% | |
| Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics | Press release | PR Newswire | -0.42% | -0.87% | |
| AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 | Press release | PR Newswire | -0.35% | -1.93% | |
| AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults | Press release | PR Newswire | +0.82% | +2.08% | |
| AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | PR Newswire | +0.82% | +2.08% | |
| Form SD AbbVie Inc. | SEC filing · Form SD | SEC EDGAR | +0.82% | +2.08% | |
| AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia | Press release | PR Newswire | -0.40% | -0.59% | |
| U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options | Press release | PR Newswire | +0.73% | +1.22% | |
| AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection | Press release | PR Newswire | +0.82% | -0.28% | |
| AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline | Press release | PR Newswire | +0.82% | -0.28% | |
| Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults | Press release | PR Newswire | +0.82% | -0.28% | |
| Form 8-K AbbVie Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | +0.79% | |
| Form 10-Q AbbVie Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.02% | +0.27% | |
| AbbVie to Present at the Bank of America Securities Healthcare Conference | Press release | PR Newswire | -0.07% | -0.52% | |
| AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week® | Press release | PR Newswire | -0.92% | -1.37% | |
| SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis | Press release | Canada Newswire | +0.03% | +1.19% | |
| AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec | Press release | GlobeNewswire | -0.07% | -0.78% | |
| Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month | Press release | PR Newswire | +0.92% | +0.73% | |
| AbbVie Reports First-Quarter 2026 Financial Results | Press release | PR Newswire | +3.00% | +6.41% | |
| Form 8-K AbbVie Inc. For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | +3.00% | +6.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ABBV section they belong to.
More of the dataset.
ABBV earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AbbVie Inc.'s median reaction calculated?
Every labeled ABBV news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 720 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of ABBV's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-18.
Does ABBV's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.